TolerogenixX

TolerogenixX is a clinical-stage biopharmaceutical company that develops personalized cell therapies designed to induce antigen-specific immune tolerance. Its proprietary Modified Immune Cell (MIC) technology produces treatments for transplant recipients and patients with autoimmune diseases like systemic lupus erythematosus and multiple sclerosis. The company's lead product candidate, MIC-Lx, aims to reduce the need for lifelong systemic immunosuppression in living-donor kidney transplantation.